5PSQ-045 Safety profile of sunitinib in real clinical practice

• Published in: European journal of hospital pharmacy. Science and practice Vol. 26; no. Suppl 1; p. A222
• Main Authors: Alcala Soto, A, Puivecino Moreno, C, Gazquez Perez, R, Varas Perez, A, Sanchez-Matamoros Piazza, V, Jimenez Pichardo, L, Vazquez Vela, V, Sierra Sanchez, JF, Gavira Moreno, R, Gomez de Travecedo Y Calvo, MT
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2019
• Subjects: Clinical medicine; Gastrointestinal cancer; Hypertension; Kidney cancer; Pancreatic cancer; Targeted cancer therapy
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2019-eahpconf.478

BackgroundIn long-term safety studies of sunitinib, most adverse events (AE) occurred initially between the first 6 months and 1 year, and remained stable or decreased in frequency over time.PurposeTo analyse the safety and tolerability of sunitinib in real clinical practice.Material and methodsRetrospective descriptive and observational analysis. All patients treated with sunitinib from April 2010 to September 2018 were selected. Variables collected were: sex, age, diagnosis, line of treatment, date of beginning and end of treatment with sunitinib, reasons for suspension, dose reductions and AE. To assess safety, frequency of adverse reactions, median time to treatment suspension due to AE, median time to dose reductions and the reasons were taken into account. Data was collected from the electronic medical record (DIRAYA) and the prescription program (FARMIS and PRISMA).ResultsThirty-five patients were included, 66% males, with an average age of 62 years. Eighty per cent of patients (n=28) had metastatic renal cell cancer (mRCC), 11% (n=4) gastrointestinal stromal tumour (GIST) and 3% (n=1) pancreatic tumor, unknown n=2. Seventy-seven per cent (27) of patients received sunitib as first-line therapy, 20% (seven) received it as second-line and 3% (one) as third-line. Most frequent AE were asthaenia (21 patients), hypertension blood pressure (HBP) (12 patients), mucositis (nine patients), anaemia (eight patients), bleeding and plantar-palmar-syndrome (six patients respectively). Ten patients discontinued treatment due to AE, median time to treatment suspension due to AE was 3.42 months (0.47–95.43) because of poor tolerance, unacceptable toxicity, haemorrhages, osteonecrosis of the jaw, asthaenia, mucositis, anorexia and liver toxicity. Of these patients, only three had previous dose reductions. Eight patients required dose reduction, with a median time to dose reduction of 1.78 months (0.97–87.37). The main cause of reduction was asthaenia (5/8). One patient had a second dose reduction 1 month after the first reduction due to poor quality of life.ConclusionReported AE were within the expected range, with asthaenia and hypertension as the most frequent. About one-third of patients discontinued treatment with sunitinib due to AE in the first 4 months of treatment and in most cases without prior dose reductions.References and/or acknowledgementshttps://www.ema.europa.eu/documents/product-information/sutent-epar-product-information_en.pdfNo conflict of interest.